Novartis gets FDA nod for Tabrecta to treat metastatic NSCLC with METex14

This article was originally published here

The approval has been granted for Tabrecta, a MET inhibitor, to treat adult patients with NSCLC whose tumours have a mutation, which leads to METex14 as detected by

The post Novartis gets FDA nod for Tabrecta to treat metastatic NSCLC with METex14 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply